**ICMJE DISCLOSURE FORM**

**Date:** January 5, 2022

**Your Name:** Runzhi Chen

**Manuscript Title:** Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

**Manuscript number (if known):** ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------|--------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | x ||
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x | None |
| 3 | Royalties or licenses | x | None |
| 4 | Consulting fees | x | None |
| **Time frame: past 36 months** | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x | None |
| 3 | Royalties or licenses | x | None |
| 4 | Consulting fees | x | None |
|   |                                                                 |   |
|---|------------------------------------------------------------------|---|
| 5 | Payment or honoraria for lectures, presentations,               | x None |
|   | speakers bureaus, manuscript writing or educational events      |   |
| 6 | Payment for expert testimony                                     | x None |
| 7 | Support for attending meetings and/or travel                    | x None |
| 8 | Patents planned, issued or pending                               | x None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory     | x None |
|   | Board                                                            |   |
| 10| Leadership or fiduciary role in other board, society, committee | x None |
|   | or advocacy group, paid or unpaid                                |   |
| 11| Stock or stock options                                          | x None |
| 12| Receipt of equipment, materials, drugs, medical writing,        | x None |
|   | gifts or other services                                         |   |
| 13| Other financial or non-financial interests                       | Jiangsu Hengrui Pharmaceutical Group Co. Ltd. |

Please summarize the above conflict of interest in the following box:

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Liu Yang

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** |                                                                                      |                                                                                        |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | x ____ None                                                                          |
|   | **No time limit for this item.**                                                               |                                                                                        |
| **Time frame: past 36 months**                                                                                             |                                                                                        |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | x ____ None                                                                          |
| 3 | Royalties or licenses                                                                          | x ____ None                                                                          |
| 4 | Consulting fees                                                                                | x ____ None                                                                          |
|   | Description                                                                                           | Response |
|---|-------------------------------------------------------------------------------------------------------|----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☒ None   |
| 6 | Payment for expert testimony                                                                         | ☒ None   |
| 7 | Support for attending meetings and/or travel                                                           | ☒ None   |
| 8 | Patents planned, issued or pending                                                                    | ☒ None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                                     | ☒ None   |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      | ☒ None   |
|11 | Stock or stock options                                                                               | ☒ None   |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                       | ☒ None   |
|13 | Other financial or non-financial interests                                                            |          |

Please summarize the above conflict of interest in the following box:

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
**ICMJE DISCLOSURE FORM**

**Date:** January 5, 2022

**Your Name:** Sheng Hu

**Manuscript Title:** Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

**Manuscript number (if known):** ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | x ____None |
|   | **No time limit for this item.** | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x ____None |
| 3 | Royalties or licenses | x ____None |
| 4 | Consulting fees | x ____None |

Time frame: Since the initial planning of the work

Time frame: past 36 months
|   | Description                                                                 | Answer | Note |
|---|-----------------------------------------------------------------------------|--------|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | x None |      |
| 6 | Payment for expert testimony                                               | x None |      |
| 7 | Support for attending meetings and/or travel                                | x None |      |
| 8 | Patents planned, issued or pending                                          | x None |      |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | x None |      |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | x None |      |
| 11| Stock or stock options                                                      | x None |      |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | x None |      |
| 13| Other financial or non-financial interests                                  | Jiangsu Hengrui Pharmaceutical Group Co. Ltd. |      |

Please summarize the above conflict of interest in the following box:

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Zhusheng Yin

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | [ ] None | Time frame: Since the initial planning of the work |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | [ ] None |
| 3 | Royalties or licenses | [ ] None |
| 4 | Consulting fees | [ ] None |
|   | Time frame: past 36 months | |
|   | Description                                                                 | Response |
|---|-----------------------------------------------------------------------------|----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | x ____None |
| 6 | Payment for expert testimony                                                | x ____None |
| 7 | Support for attending meetings and/or travel                                | x ____None |
| 8 | Patents planned, issued or pending                                          | x ____None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | x ____None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | x ____None |
| 11| Stock or stock options                                                      | x ____None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | x ____None |
| 13| Other financial or non-financial interests                                  | Jiangsu Hengrui Pharmaceutical Group Co. Ltd. |

Please summarize the above conflict of interest in the following box:

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

  x I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Yanli Nie

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | x ___ None |
|   | **No time limit for this item.** | |

|   | Time frame: Since the initial planning of the work |
|---|--------------------------------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x ___ None |
| 3 | Royalties or licenses | x ___ None |
| 4 | Consulting fees | x ___ None |

|   | Time frame: past 36 months |
|---|-----------------------------|
|   | |
|   | Description                                                                 | Response |
|---|------------------------------------------------------------------------------|----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | x None   |
| 6 | Payment for expert testimony                                                 | x None   |
| 7 | Support for attending meetings and/or travel                                 | x None   |
| 8 | Patents planned, issued or pending                                           | x None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board             | x None   |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | x None   |
|11 | Stock or stock options                                                       | x None   |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | x None   |
|13 | Other financial or non-financial interests                                   | Jiangsu Hengrui Pharmaceutical Group Co. Ltd. |

Please summarize the above conflict of interest in the following box:

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Hongli Xu

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | x ____ None |
|   | **No time limit for this item.**                                                                                                   |                                                                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                            | x ____ None |
| 3 | Royalties or licenses                                                                                                               | x ____ None |
| 4 | Consulting fees                                                                                                                     | x ____ None |

Time frame: Since the initial planning of the work

Time frame: past 36 months
|   | Description                                                                 | Response |
|---|-----------------------------------------------------------------------------|----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | x None   |
| 6 | Payment for expert testimony                                                | x None   |
| 7 | Support for attending meetings and/or travel                                | x None   |
| 8 | Patents planned, issued or pending                                          | x None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | x None   |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | x None   |
|11 | Stock or stock options                                                      | x None   |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | x None   |
|13 | Other financial or non-financial interests                                  | Jiangsu Hengrui Pharmaceutical Group Co. Ltd. |

Please summarize the above conflict of interest in the following box:

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Yi Zhong

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Time frame: Since the initial planning of the work |
|-----------------|---------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. |
| | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | x _____ None | |
| | | |
| | | |
| | | |
| | | |
| | | |

| Time frame: past 36 months |
|-----------------|---------------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). |
| | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | x _____ None | |
| | | |
| | | |
| | | |
| | | |

| 3 | Royalties or licenses |
| | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | x _____ None | |
| | | |
| | | |

| 4 | Consulting fees |
| | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | x _____ None | |
| | | |
| | | |
|   | Description                                                                 | Agreement | Notes |
|---|------------------------------------------------------------------------------|-----------|-------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | X None    |       |
| 6 | Payment for expert testimony                                                  | X None    |       |
| 7 | Support for attending meetings and/or travel                                  | X None    |       |
| 8 | Patents planned, issued or pending                                            | X None    |       |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board             | X None    |       |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | X None    |       |
| 11| Stock or stock options                                                        | X None    |       |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | X None    |       |
| 13| Other financial or non-financial interests                                   | Jiangsu Hengrui Pharmaceutical Group Co. Ltd. |       |

Please summarize the above conflict of interest in the following box:

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Yuze Zhu

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | x ____ None                                                                     |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | x ____ None                                                                     |
| 3 | Royalties or licenses                                                                           | x ____ None                                                                     |
| 4 | Consulting fees                                                                                 | x ____ None                                                                     |
|   | Description                                                                 | X | None |
|---|------------------------------------------------------------------------------|----|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | x   | None |
| 6 | Payment for expert testimony                                                | x   | None |
| 7 | Support for attending meetings and/or travel                                 | x   | None |
| 8 | Patents planned, issued or pending                                           | x   | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            | x   | None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | x   | None |
|11 | Stock or stock options                                                       | x   | None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | x   | None |
|13 | Other financial or non-financial interests                                   |     | None |

Please summarize the above conflict of interest in the following box:

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: January 5, 2022

Your Name: Xinjun Liang

Manuscript Title: Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study

Manuscript number (if known): ATM-22-77

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | **Time frame: Since the initial planning of the work**                                      |                                                                                 |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | x _____None                                                                       |
|   | **No time limit for this item.**                                                               |                                                                                 |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | x _____None                                                                       |
| 3 | Royalties or licenses                                                                         | x _____None                                                                       |
| 4 | Consulting fees                                                                               | x _____None                                                                       |

**Time frame: past 36 months**

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | x _____None                                                                       |
| 3 | Royalties or licenses                                                                         | x _____None                                                                       |
| 4 | Consulting fees                                                                               | x _____None                                                                       |
|   | Description                                                                 | Answer | Notes |
|---|-----------------------------------------------------------------------------|--------|-------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | x None |       |
| 6 | Payment for expert testimony                                                | x None |       |
| 7 | Support for attending meetings and/or travel                                | x None |       |
| 8 | Patents planned, issued or pending                                           | x None |       |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            | x None |       |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | x None |       |
| 11| Stock or stock options                                                       | x None |       |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | x None |       |
| 13| Other financial or non-financial interests                                   | Jiangsu Hengrui Pharmaceutical Group Co. Ltd. |       |

Please summarize the above conflict of interest in the following box:

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

x I certify that I have answered every question and have not altered the wording of any of the questions on this form.
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | **Time frame: Since the initial planning of the work** |                                                                                 |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | x None |
|   | Question                                                                 | Answer |
|---|--------------------------------------------------------------------------|--------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,    | None   |
|   | manuscript writing or educational events                                 |        |
| 6 | Payment for expert testimony                                             | None   |
| 7 | Support for attending meetings and/or travel                             | None   |
| 8 | Patents planned, issued or pending                                       | None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board        | None   |
| 10| Leadership or fiduciary role in other board, society, committee or      | None   |
|   | advocacy group, paid or unpaid                                           |        |
| 11| Stock or stock options                                                   | None   |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other  | None   |
|   | services                                                                  |        |
| 13| Other financial or non-financial interests                                | None   |
|   | Jiangsu Hengrui Pharmaceutical Group Co. Ltd.                            |        |

Please summarize the above conflict of interest in the following box:

The study protocol was supported by the Jiangsu Hengrui Pharmaceutical Group Co. Ltd.

Please place an “X” next to the following statement to indicate your agreement:

✓ I certify that I have answered every question and have not altered the wording of any of the questions on this form.